OralTherapeutic flag Cosmetic cross-reference

Methenamine

CAS 100-97-0

Methenamine (CAS 100-97-0) is a Phase 4 pharmaceutical compound with 3 bioactivity targets and 177 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
3
SOURCE DrugCentral / FAERS
Adverse signals
177
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Methenamine
CAS Number
100-97-0
UNII
J50OIX95QV
InChIKey
VKYKSIONXSXAKP-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1201270
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural productoraltherapeutic flag
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1201270 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE ChEMBL 36 activities + assays 3 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 26802.02285714286 nM 35 -
- Potency 46143.700000000004 nM 2 -
- IC50 19976.309999999998 nM 1 -
SOURCE DrugCentral 2023 / FAERS disproportionality 10 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Urinary tract infection 101 128.57 10046571
Thyroid cancer metastatic 5 26.463 10055107
Multiple sclerosis 14 23.342 10028245
Drug monitoring procedure not performed 6 23.319 10075462
Secondary progressive multiple sclerosis 6 21.407 10063400
Urine analysis abnormal 8 20.038 10062226
Fatigue 92 19.939 10016256
Pathogen resistance 11 19.677 10034133
Cystitis 17 19.282 10011781
Osteitis 7 19.08 10031149

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE RxNorm drug names 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
METHENAMINE 6832 SU MTHSPL
methenamine 6832 IN RXNORM
SOURCE SIDER side-effect resource 29 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Abdominal discomfort methenamine PT C0232487
Abdominal discomfort methenamine PT C0232487
Dermatitis methenamine PT C0011603
Dermatitis methenamine PT C0011603
Digestion impaired methenamine LLT C0232459
Dyspepsia methenamine PT C0013395
Dysuria methenamine LLT C0013428
Dysuria methenamine PT C0013428
Dysuria methenamine LLT C0013428
Dysuria methenamine PT C0013428
Frank hematuria methenamine LLT C0473237
Gastrointestinal disorder methenamine PT C0017178
Haematuria methenamine PT C0018965
Nausea methenamine LLT C0027497
Nausea methenamine PT C0027497
Nausea methenamine LLT C0027497
Nausea methenamine PT C0027497
Pruritus methenamine LLT C0033774
Pruritus methenamine PT C0033774
Pyuria methenamine LLT C0034359
Pyuria methenamine PT C0034359
Rash methenamine LLT C0015230
Rash methenamine PT C0015230
Rash methenamine LLT C0015230
Rash methenamine PT C0015230
Upset stomach methenamine LLT C0235309
Upset stomach methenamine LLT C0235309
Vomiting methenamine LLT C0042963
Vomiting methenamine PT C0042963
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Methenamine used for in pharmaceutical contexts?

Methenamine (CAS 100-97-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Methenamine?

Methenamine has 177 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Urinary tract infection, Thyroid cancer metastatic, Multiple sclerosis, Drug monitoring procedure not performed, Secondary progressive multiple sclerosis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Methenamine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Methenamine with EU status "restricted".

What clinical phase is Methenamine in?

Methenamine is rendered with ChEMBL max phase 4 (approved).